Deubiquitinases in cancer

G Dewson, PJA Eichhorn, D Komander - Nature Reviews Cancer, 2023‏ - nature.com
Ubiquitination is an essential regulator of most, if not all, signalling pathways, and defects in
cellular signalling are central to cancer initiation, progression and, eventually, metastasis …

Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials

Z Niu, R **, Y Zhang, H Li - Signal Transduction and Targeted Therapy, 2022‏ - nature.com
Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer

JK Nelson, MZ Thin, T Evan, S Howell, M Wu… - Nature …, 2022‏ - nature.com
Deubiquitylating enzymes (DUBs) play an essential role in targeted protein degradation and
represent an emerging therapeutic paradigm in cancer. However, their therapeutic potential …

Protein degradation: expanding the toolbox to restrain cancer drug resistance

H Ming, B Li, J Jiang, S Qin, EC Nice, W He… - Journal of Hematology & …, 2023‏ - Springer
Despite significant progress in clinical management, drug resistance remains a major
obstacle. Recent research based on protein degradation to restrain drug resistance has …

TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer

WL Ye, L Huang, XQ Yang, S Wan, WJ Gan… - Proceedings of the …, 2024‏ - pnas.org
Kirsten rat sarcoma virus (KRAS) mutation is associated with malignant tumor transformation
and drug resistance. However, the development of clinically effective targeted therapies for …

USP28 controls SREBP2 and the mevalonate pathway to drive tumour growth in squamous cancer

CR Maier, O Hartmann, C Prieto-Garcia… - Cell Death & …, 2023‏ - nature.com
SREBP2 is a master regulator of the mevalonate pathway (MVP), a biosynthetic process that
drives the synthesis of dolichol, heme A, ubiquinone and cholesterol and also provides …

Structural basis for the bi-specificity of USP25 and USP28 inhibitors

JV Patzke, F Sauer, RK Nair, E Endres, E Proschak… - EMBO …, 2024‏ - embopress.org
The development of cancer therapeutics is often hindered by the fact that specific
oncogenes cannot be directly pharmaceutically addressed. Targeting deubiquitylases that …

PTBP1 drives c-Myc-dependent gastric cancer progression and stemness

T Ni, Z Chu, L Tao, Y Zhao, M Zhu, Y Luo… - British Journal of …, 2023‏ - nature.com
Background Gastric cancer (GC) tumorigenesis and treatment failure are caused by cancer
stem cells. Polypyrimidine tract binding protein 1 (PTBP1) was shown to be involved in the …

Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development

X Ren, M Jiang, P Ding, X Zhang, X Zhou… - … Hematology & Oncology, 2023‏ - Springer
As significant posttranslational modifications, ubiquitination and deubiquitination, whose
balance is modulated by ubiquitin-conjugating enzymes and deubiquitinating enzymes …

Recent advances in the development of deubiquitinases inhibitors as antitumor agents

LL Zheng, LT Wang, YW Pang, LP Sun, L Shi - European Journal of …, 2024‏ - Elsevier
Ubiquitination is a type of post-translational modification that covalently links ubiquitin to a
target protein, which plays a critical role in modulating protein activity, stability, and …